How would you like your name to appear on your certificate?

Profession

What activities did you attend at the event?

Friday, November 16 - 1:10 pm - John Roberts, MD

Friday, November 16 - 1:30 pm - Ryutaro Hirose, MD

Friday, November 16 - 2:00 pm - Francis Yao, MD

Friday, November 16 - 2:30 pm - Bilal Hameed, MD

Friday, November 16 - 3:30 pm - Stephen Tomlanovich, MD and Sandy Feng, MD, PhD

Friday, November 16 - 4:00 pm - Andrew Posselt, MD, PhD

Friday, November 16 - 4:30 pm - Norah Terrault, MD, MPH

Friday, November 16 - 5:00 - 5:30 pm - Q & A

Saturday, November 17 - 9:00 am - Jennifer Lai, MD, MBA and Marion Peters, MD

Saturday, November 17 - 10:00 am - Danielle Brandman, MD, MAS and Oren Fix, MD, MSc, FACP

Saturday, November 17 - 11:00 am - Sang-Mo Kang, MD and Chris Friese, MD

Agreement

By completing this form, you attest that you have participated in all selected activities in thier entirety.

I agree

Please rate the speaker(s) as a group. You will have the opportunity to elaborate on an individual speaker in the following question.

Please rate the following:

The program was relevant to my work.

Content matched stated objectives.

Usefulness of handouts/AV.

Quality of facilities.

How well did the educational sessions give a balanced view of therapeutic options, including the use of generic names?

If you rated any of the above questions with 'fair,' 'poor,' 'disagree,' or 'strongly disagree' please explain in detail (e.g. session title, speaker name, situtation):

If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:

Having attended this session, how well are you able to meet the following objectives:

Explain the rationale for the different HCV treatment strategies in transplant patients with HCV.

Recognize the best candidates for consideration of pre-transplant HCV therapy, and the adjuvant measures used to reduce the risks of complications.

List potential risks and benefits of post-transplant treatment with protease inhibitor triple therapy, especially in regards to drug-drug interactions.

Review the anticipated new treatment strategies, especially interferon-free regimens and how these may be applied to cirrhotics and transplant recipients

Having completed the activity, please rate your ability to meet each of the following objectives:

Discuss the fact that the UCSF graft survival statistics are better than expected as compared to national data.

State the percentage of patients that die each year while waiting for a transplant.

Describe the current liver allocation system in the U.S., and how it has evolved

Identify and describe some of the shortcomings of the current allocation system

Explain the relevant practical and political considerations with respect to proposed changes in the allocation system

Discuss the proposed changes in liver allocation, and some of the different models that could be used to distribute liver grafts

Discuss the current status of selection criteria for liver transplant in patients with hepatocellular carcinoma.

Define the roles of local regional therapy as a bridge to liver transplant.

Explain the problems and controversies related to organ allocation policies for patients with hepatocellular carcinoma.

Discuss management of portal vein thrombosis in cirrhosis.

Identify patients who are candidates for broad spectrum antibiotics in decompensated disease.

Describe outcomes of liver transplant in patients with renal disease prior to transplant.

List the current consensus indications for dual liver-kidney transplant.

Compare the various bariatric procedures being used today.

Describe the effects of obesity on liver transplant outcomes.

Discuss the outcomes of bariatric surgery in patients with liver disease - improvement in overall health and candidacy for transplantation.

Identify patients who are at increased risk for HBV reactivation.

Describe how to recognize and manage HBV viral resistance.

Define the role of liver biopsy in the diagnosis and management of acute liver failure.

Recognize malignancy as a cause of acute liver failure.

Name a form of amyloidosis that can primarily affect the liver and cause acute liver failure treatable with liver transplantation.

Describe the decision making process to determine type of portal blood flow modulation in living donor liver transplantation.

Describe the pathogenesis of small for size syndrome.

Identify the risks and benefits of choosing a left lobe living donor over a right lobe living donor.

Objective 1: Discuss the latest developments in management of liver transplant candidates based on specific disease indications.

By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.

By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.

By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.

Objective 2: Manage patients with hepatorenal failure and explain the controversies regarding the need for combined liver and kidney transplant.

By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.

By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.

By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.

Objective 3: Describe the management of specific liver diseases such as complications of viral heptatitis, portal hypertension and bariatric surgery.

By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.

By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.

By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.

Please answer the following:

Do you believe this activity was appropriate for the scope of your professional activities?

Was the educational content scientifically sound?

If faculty spoke about off-label or investigational uses of a product, was that information disclosed to you?

Was the mode of education effective to learning?

If you answered "No" to any of the above questions, please explain.

Did you perceive any product/service/company/commercial bias in any educational session you attended or materials you received?

If you answered "Yes" to the above question, please detail the situation below (e.g. session title, speaker name):

Were you solicited by sales personnel in an educational room (other areas do not matter) while you attended this educational activity?

If you answered "Yes" to the above question, please explain in detail (e.g. who, when, where):

How much did you learn as a result of this education program?

What specifically did you learn during this activity that you intend to integrate into your practice?

What questions have arisen in your practice for which you need answers/strategies that you can implement?

What patient/client problems or patient/client challenges do you feel you are not able to address appropriately or to your satisfaction?

What problems are your patients/clients communicating to you that need attention or follow up?

Are you interested in basic, intermediate or advanced level trainings?

Basic

Intermediate

Advanced

What barriers might you have that would interfere with implementation of new information learned from this training?

How can this training (the overall meeting) be improved to better impact competence, performance and/or patient/client outcomes?

Additional comments: